Yes you read correctly Skunk!
Hemp Houd are on the trail again and all of this sounds very on the nose..
On 08/02/25 The Hemp Hound Agency submitted a Freedom of Information Request (FOI) to the MHRA with several questions regarding Cannabidiol (CBD) and Cannabis sativa.
This article will go through their response, which was received on 07/03/25.
‘Killing in the name of‘ looked at the absurdity of some of the recorded cases, and questioned the legitimacy of including CBD supplemental products in lists that are meant to record adverse reactions to medicines and vaccines. The MHRA’s FOI response states that the names of products causing reactions do not have to be reported—somewhat concerning, especially given their admission that some reactions could be logged on a ‘guilt by association’ basis.
The questions asked to the MHRA were:
1. The date when ‘Skunk’ was first listed under the Yellow Card Scheme for Cannabis sativa.
2. The date when CBD supplemental products were first recorded under the Yellow Card
Scheme for Cannabis sativa.
3. The date when CBD products were first listed under the Yellow Card Scheme for CBD specifically.
4. Confirmation that the Yellow Card Scheme is primarily intended for recording adverse reactions to licensed medicines and vaccines.
Additionally requested:
7. If the reports in requests 5 and 6 are not associated with recognised products, can the MHRA confirm whether the fatalities in question were linked to medical trials?
If full disclosure was not possible for requests 5, 6, and 7, a further request was added for:
8. The reason under FOI exemptions for withholding this information.
9. Any general categorisation of the products (e.g., pharmaceutical, consumer, investigational use).
The full response
Now that you’re prepped, let’s break down the MHRA’s response—but be warned, it’s filled with contradictions and deflections.
Certain questions will be asked, some of which I will answer, whereas others are open to consideration based on available information.
That being said, I encourage discussion on the interpretation and implications of the information provided.
Question 1: The date when ‘Skunk’ was first listed under the Yellow Card Scheme for Cannabis sativa.
Response: The first UK spontaneous suspected adverse drug reaction (ADR) report we received where the suspect drug was reported using the term “skunk” was received on 15/03/2018.
Analysis
Suspected… that would be the first indicator of some reports working on a ‘guilt by association’ basis.
Skunk is a term for illicit high-THC cannabis, not a regulated pharmaceutical product. The only way its presence would make sense is if the medicine in question was actually made from Skunk #1—which, conveniently, happens to be owned by GW Pharmaceuticals.
